Development of personalized combination cancer immunotherapy based on the patients’ immune status

Inflammation and Immunity in Cancer

Volumn , Issue , 2015, Pages 255-266

  Kawakami, Yutaka ^a   Qian, Li ^a   Kawamura, Naoshi ^a   Miyazaki, Junichiro ^a   Nagumo, Haruna ^a   Tsubota, Kinya ^a   Kinoshita, Tomonari ^a   Nakamua, Kenta ^a   Ohmura, Gaku ^a   Satomi, Ryosuke ^a   Sugiyama, Juri ^a   Nishio, Hiroshi ^a   Hayakawa, Taeko ^a   Popivanova, Boryana ^a   Nuchsupha, Sunthamala ^a   Hsin Ju Liu, Tracy ^a   Kamijuku, Hajime ^a   Kudo Saito, Chie ^a   Tsukamoto, Nobuo ^a   Sakurai, Toshiharu ^a   Fujita, Tomonobu ^a   Yaguchi, Tomonori ^a   more..

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarkers; Cancer immunopathology; Cancer immunotherapy; Combination immunotherapy; Personalized therapy

Indexed keywords

EID: 84943385960     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-55327-4_20     Document Type: Chapter

References (39)

1. Bindea G, Mlecnik B, Tosolini M et al (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39:782–795
2. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
3. Fridman WH, Pagès F, Sautès-Fridman C et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306
4. Galon J, Mlecnik B, Bindea G et al (2014) Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 232(2):199–209
5. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
6. Ishikawa T, Fujita T, Suzuki Y et al (2003) Tumor-specific immunological recognition of frameshift- mutated peptides in colon cancer with microsatellite instability. Cancer Res 63:5564–5572
7. Iwata-Kajihara T, Sumimoto H et al (2011) Enhanced cancer immunotherapy using STAT3- depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol 187:27–36
8. Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95
9. Kawakami Y, Eliyahu S, Delgado CH et al (1994a) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515–3519
10. Kawakami Y, Eliyahu S, Delgado CH et al (1994b) Identification of human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc NatlAcad Sci U S A 91:6458–6462
11. Kawakami Y, Eliyahu S, Sakaguchi K et al (1994c) Identification of the immune dominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 180:347–352
12. Kawakami Y, Wang X, Shofuda T et al (2001) Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor infiltrating T lymphocytes. J Immunol 166:2871–2877
13. Kawakami Y, Yaguchi T, Sumimoto H et al (2013a) Roles of signaling pathways in cancer cells and immune cells in generation of immunosuppressive tumor-associated microenvironments. In: Shurin M, Malyguine A, Umansky V (eds) Tumor immune environment. Dordrecht/Heidelberg/New York/London
14. Kawakami Y, Yaguchi T, Sumimoto H et al (2013b) Improvement of cancer immunotherapy by combining molecular targeted therapy. Front Oncol 3:136
15. Kudo-Saito C, Shirako H, Takeuchi T et al (2009) Cancer metastasis is accelerated through immunosuppression during EMT of cancer cell. Cancer Cell 16:195–206
16. Kudo-Saito C, Shirako H, Ohike M et al (2012) CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis 30:393–405
17. Mlecnik B, Bindea G, Angell HK et al (2014) Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 6:228
18. Nakamura S, Yaguchi T, Kawamura N et al (2014) TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression. J Immunother 37:63–72
19. Nishio H, Yaguchi T, Sugiyama J et al (2014) Immunosuppression through constitutively activatedNF-κB signaling in human ovarian cancer and its reversal by a NF-κB inhibitor. Br J Cancer 110:2965–2974
20. Ohkusu-Tsukada K, Ohta S, Kawakami Y et al (2011) Adjuvant effects of formalin-inactivated HSV through activation of dendritic cells and inactivation of myeloid-derived suppressor cells in cancer immunotherapy. Int J Cancer 128:119–131
21. Pagès F, Kirilovsky A, Mlecnik B et al (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27:5944–5951
22. Robbins PF, El-Gamil M, Li YF et al (1996) A mutated b2-catenin gene encodes a melanoma –specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183:1185–1192
23. Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive withNY-ESO-1. J Clin Oncol 29:917–924
24. Robbins PF, Lu YC, El-Gamil M et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747–752
25. Rosenberg SA, Yang J, Schwartzentruber D et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327
26. Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550–4557
27. Salgaller M, Marincola F, Rivoltini L et al (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by antigen specific peripheral blood lymphocytes stimulated with synthetic peptides. Cancer Res 55:4972–4979
28. Schreiber RD et al (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570
29. Sumimoto H, Imabayashi F, Iwata T et al (2006) The BRAF-MAPK signaling pathway is essential for cancer immune evasion in human melanoma cells. J Exp Med 203:1651–1656
30. Taube JM, Anders RA, Young GD et al (2014) Colocalization of inflammatory response withB7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127
31. Toda M, Iizuka Y, Kawase T et al (2002) Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther 9:356–364
32. Topalian SL, Hodi FS, Brahmer JR et al (2013) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
33. Udagawa M, Kudo-Saito C, Hasegawa G et al (2006) Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res 12:7465–7475
34. Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M (2004) Identification of a human glioma antigen, SOX6, recognized by patients’ sera. Oncogene 23:1420–1427
35. Ueda R, Ohkusu-Tsukada K, Fusaki N et al (2010) Identification of HLA-A2- and A24-restrictedT-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer 126:919–929
36. Wagle N, Emery C, Berger MF et al (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085–3096
37. Wilmott JS, Long GV, Howle JR et al (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386–1394
38. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y et al (2011) The mechanisms of cancer immune escape and development of overcoming strategies. Int J Hematol 93:294
39. Yaguchi T, Goto Y, Kido K, Mochimaru H et al (2012) Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol 189:2110–2117